Skip to main content

2016 First Annual Oncology Guide to New FDA Approvals

FDA Updates
Keytruda (Pembrolizumab): First PD-1 Inhibitor Approved for the Treatment of Patients with Metastatic Non–Small-Cell Lung Cancer Expressing PD-L1
Lisa A. Raedler, PhD, RPh, Medical Writer
Read More
FDA Updates
A Pipeline Preview of 2016 FDA Approvals in Hematology/Oncology
Ryan Beechinor, PharmD, BCPS, CPP, John M. Valgus, PharmD, MHA, BCOP
Read More
FDA Updates
Zarxio (Filgrastim-sndz): First Biosimilar Approved in the United States
Lisa A. Raedler, PhD, RPh, Medical Writer
Read More
FDA Updates
Varubi (Rolapitant) Approved for the Prevention of Delayed-Onset Chemotherapy-Induced Nausea and Vomiting
Lisa A. Raedler, PhD, RPh, Medical Writer
Read More
FDA Updates
Revlimid (Lenalidomide) Now FDA Approved as First-Line Therapy for Patients with Multiple Myeloma
Lisa A. Raedler, PhD, RPh, Medical Writer
Read More
FDA Updates, Monoclonal Antibodies
Portrazza (Necitumumab), an IgG1 Monoclonal Antibody, FDA Approved for Advanced Squamous Non–Small-Cell Lung Cancer
Loretta Fala, Medical Writer
Read More
FDA Updates
Pomalyst (Pomalidomide) Received a New Indication for Patients with Relapsed and/or Refractory Multiple Myeloma
Lisa A. Raedler, PhD, RPh, Medical Writer
Read More
FDA Updates
Ninlaro (Ixazomib): First Oral Proteasome Inhibitor Approved for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
Lisa A. Raedler, PhD, RPh, Medical Writer
Read More
FDA Updates
Lonsurf (Trifluridine plus Tipiracil): A New Oral Treatment Approved for Patients with Metastatic Colorectal Cancer
Lisa A. Raedler, PhD, RPh, Medical Writer
Read More
FDA Updates
Welcome to the First Annual Oncology Pharmacy Guide to New FDA Approvals
Read More
Page 1 of 2
Results 1 - 10 of 18